Compare Stocks: EYPT, HROW, AMPH, and ANRO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMPH Amphastar Pharmaceuticals	$25.70 +1.3%	$22.69	$16.65 ▼ $29.52	$1.09B	0.9	518,470 shs	104,400 shs
ANRO Alto Neuroscience	$24.24 +1.0%	$31.02	$5.22 ▼ $37.48	$949.46M	1.31	405,491 shs	167,605 shs
EYPT Eyepoint Pharmaceuticals	$3.24 +2.7%	$6.68	$3.05 ▼ $19.11	$278.89M	1.67	2.12 million shs	577,305 shs
HROW Harrow	$30.59 +0.0%	$36.99	$28.54 ▼ $54.85	$1.15B	0.19	695,627 shs	134,184 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMPH Amphastar Pharmaceuticals	-0.24%	-7.37%	+9.45%	+26.34%	-5.16%
ANRO Alto Neuroscience	-3.22%	-10.11%	-32.75%	-6.86%	+248.86%
EYPT Eyepoint Pharmaceuticals	-3.08%	-4.83%	-31.22%	-77.53%	-77.06%
HROW Harrow	+0.33%	-3.23%	-20.65%	-33.74%	-32.69%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMPH Amphastar Pharmaceuticals	$25.70 +1.3%	$22.69	$16.65 ▼ $29.52	$1.09B	0.9	518,470 shs	104,400 shs
ANRO Alto Neuroscience	$24.24 +1.0%	$31.02	$5.22 ▼ $37.48	$949.46M	1.31	405,491 shs	167,605 shs
EYPT Eyepoint Pharmaceuticals	$3.24 +2.7%	$6.68	$3.05 ▼ $19.11	$278.89M	1.67	2.12 million shs	577,305 shs
HROW Harrow	$30.59 +0.0%	$36.99	$28.54 ▼ $54.85	$1.15B	0.19	695,627 shs	134,184 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMPH Amphastar Pharmaceuticals	-0.24%	-7.37%	+9.45%	+26.34%	-5.16%
ANRO Alto Neuroscience	-3.22%	-10.11%	-32.75%	-6.86%	+248.86%
EYPT Eyepoint Pharmaceuticals	-3.08%	-4.83%	-31.22%	-77.53%	-77.06%
HROW Harrow	+0.33%	-3.23%	-20.65%	-33.74%	-32.69%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMPH Amphastar Pharmaceuticals	1.75	Reduce	$22.50	-12.43% Downside
ANRO Alto Neuroscience	2.64	Moderate Buy	$37.25	53.65% Upside
EYPT Eyepoint Pharmaceuticals	2.27	Hold	$25.70	694.44% Upside
HROW Harrow	2.60	Moderate Buy	$66.17	116.30% Upside

Current Analyst Ratings Breakdown

Latest EYPT, HROW, AMPH, and ANRO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/9/2026	HROW Harrow	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$45.00
9/9/2026	HROW Harrow	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
9/9/2026	HROW Harrow	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$45.00
9/2/2026	EYPT Eyepoint Pharmaceuticals	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold	$20.00 ➝ $4.00
9/1/2026	EYPT Eyepoint Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/20/2026	ANRO Alto Neuroscience	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/18/2026	AMPH Amphastar Pharmaceuticals	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$20.00 ➝ $23.00
8/18/2026	EYPT Eyepoint Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$17.00
8/18/2026	EYPT Eyepoint Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$5.00
8/18/2026	EYPT Eyepoint Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform ➝ Sector Perform	$5.00
8/18/2026	EYPT Eyepoint Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral

(Data available from 10/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMPH Amphastar Pharmaceuticals	$730.02M	1.50	$4.30 per share	5.98	$17.17 per share	1.50
ANRO Alto Neuroscience	N/A	N/A	N/A	N/A	$4.87 per share	N/A
EYPT Eyepoint Pharmaceuticals	$31.37M	8.89	N/A	N/A	$3.70 per share	0.87
HROW Harrow	$275.59M	4.16	$0.87 per share	35.27	$1.41 per share	21.70

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMPH Amphastar Pharmaceuticals	$98.09M	$1.69	15.20	9.92	4.90	10.76%	14.98%	6.96%	11/5/2026 (Estimated)
ANRO Alto Neuroscience	-$63.24M	-$2.42	N/A	N/A	N/A	N/A	-46.46%	-39.09%	11/11/2026 (Estimated)
EYPT Eyepoint Pharmaceuticals	-$231.96M	-$3.74	N/A	N/A	N/A	-10,994.73%	-135.81%	-108.35%	11/4/2026 (Estimated)
HROW Harrow	-$5.14M	-$1.00	N/A	14.03	N/A	-13.51%	-38.00%	-3.37%	11/9/2026 (Estimated)

Latest EYPT, HROW, AMPH, and ANRO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	ANRO Alto Neuroscience	-$0.7345	-$0.65	+$0.0845	-$0.65	N/A	N/A
8/10/2026	Q2 2026	HROW Harrow	-$0.1788	-$0.46	-$0.2813	-$0.46	$70.35 million	$70.66 million
8/6/2026	Q2 2026	AMPH Amphastar Pharmaceuticals	$0.62	$0.91	+$0.29	$0.67	$179.92 million	$183.90 million
8/5/2026	Q2 2026	EYPT Eyepoint Pharmaceuticals	-$1.01	-$1.09	-$0.08	-$0.2720	$0.45 million	$0.51 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMPH Amphastar Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ANRO Alto Neuroscience	N/A	N/A	N/A	N/A	N/A
EYPT Eyepoint Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
HROW Harrow	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMPH Amphastar Pharmaceuticals	0.79	2.40	1.71
ANRO Alto Neuroscience	0.07	14.85	14.85
EYPT Eyepoint Pharmaceuticals	N/A	4.50	4.46
HROW Harrow	19.70	2.24	2.08

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMPH Amphastar Pharmaceuticals	65.09%
ANRO Alto Neuroscience	N/A
EYPT Eyepoint Pharmaceuticals	99.41%
HROW Harrow	72.76%

Insider Ownership

Company	Insider Ownership
AMPH Amphastar Pharmaceuticals	29.60%
ANRO Alto Neuroscience	11.25%
EYPT Eyepoint Pharmaceuticals	5.13%
HROW Harrow	12.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMPH Amphastar Pharmaceuticals	1,976	42.54 million	29.95 million	Optionable
ANRO Alto Neuroscience	68	39.24 million	34.83 million	N/A
EYPT Eyepoint Pharmaceuticals	214	86.21 million	81.79 million	Optionable
HROW Harrow	373	37.49 million	32.69 million	Optionable

EYPT, HROW, AMPH, and ANRO Headlines

Recent News About These Companies

Lantheus (NASDAQ:LNTH) versus Harrow (NASDAQ:HROW) Head to Head Comparison

October 6 at 4:45 AM | americanbankingnews.com

Harrow closes acquisition of TYRVAYA from Viatris

October 5 at 12:42 AM | grafa.comG

Harrow (NASDAQ: HROW) closes TYRVAYA deal, adds up to $70 million in milestones

October 5 at 1:02 PM | americanbankingnews.com

Harrow Closes Acquisition of TYRVAYA®

October 5 at 7:00 AM | globenewswire.com

Harrow Announces 15 Scientific Abstracts Featuring Data from Across Its Ophthalmic Portfolio to Be Presented At Aaopt and Aao

September 30, 2026 | marketscreener.comM

Harrow, Inc. (NASDAQ:HROW) Stock Has Average Target Price of $66.17

September 30, 2026 | americanbankingnews.com

Harrow Ophthalmic Portfolio Highlighted in 15 Scientific Presentations at AAOpt and AAO

September 30, 2026 | globenewswire.com

Harrow, Inc. (NASDAQ:HROW) Stock Now Rated "Moderate Buy" by Sell-Side Brokerages

September 30, 2026 | marketbeat.com

Contrasting Supernus Pharmaceuticals (NASDAQ:SUPN) and Harrow (NASDAQ:HROW)

September 30, 2026 | americanbankingnews.com

Bank of America Corp DE Makes New $4.57 Million Investment in Harrow, Inc. $HROW

September 29, 2026 | marketbeat.com

Harrow (NASDAQ:HROW) Stock Price Down 6.8% - Should You Sell?

September 28, 2026 | marketbeat.com

Harrow, Inc. (HROW) Stock Price, News, Quote & History - Yahoo Finance

September 15, 2026 | finance.yahoo.com

Harrow (NASDAQ:HROW) Stock Price Down 4.9% - Time to Sell?

September 11, 2026 | marketbeat.com

Harrow (NASDAQ:HROW) Upgraded by Zacks Research to Hold Rating

September 11, 2026 | marketbeat.com

Harrow, Inc. $HROW Stock Position Cut by Opaleye Management Inc.

September 11, 2026 | marketbeat.com

Leerink Partners initiates coverage of Harrow at outperform

September 10, 2026 | msn.com

Harrow (NASDAQ:HROW) Raised to "Strong-Buy" at Leerink Partners

September 10, 2026 | marketbeat.com

Leerink Partners Initiates Coverage on Harrow With Outperform Rating, $45 Price Target

September 9, 2026 | marketscreener.comM

Legal & General Group Plc Buys Shares of 26,822 Harrow, Inc. $HROW

September 8, 2026 | marketbeat.com

Bank of New York Mellon Corp Invests $3.62 Million in Harrow, Inc. $HROW

September 7, 2026 | marketbeat.com

Harrow Health Streamlines Senior Finance and Accounting Leadership

September 4, 2026 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

EYPT, HROW, AMPH, and ANRO Company Descriptions

Amphastar Pharmaceuticals NASDAQ:AMPH

$25.70 +0.33 (+1.28%)

As of 11:48 AM Eastern

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Alto Neuroscience NYSE:ANRO

$24.24 +0.23 (+0.97%)

As of 11:48 AM Eastern

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient. The company was incorporated in 2019 and is headquartered in Los Altos, California.

Eyepoint Pharmaceuticals NASDAQ:EYPT

$3.24 +0.09 (+2.70%)

As of 11:48 AM Eastern

EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

Harrow NASDAQ:HROW

$30.59 +0.01 (+0.03%)

As of 11:48 AM Eastern

Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest EYPT, HROW, AMPH, and ANRO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest EYPT, HROW, AMPH, and ANRO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

EYPT, HROW, AMPH, and ANRO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

EYPT, HROW, AMPH, and ANRO Company Descriptions

Amphastar Pharmaceuticals NASDAQ:AMPH

Alto Neuroscience NYSE:ANRO

Eyepoint Pharmaceuticals NASDAQ:EYPT

Harrow NASDAQ:HROW

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest EYPT, HROW, AMPH, and ANRO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest EYPT, HROW, AMPH, and ANRO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

EYPT, HROW, AMPH, and ANRO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

EYPT, HROW, AMPH, and ANRO Company Descriptions

Amphastar Pharmaceuticals NASDAQ:AMPH

Alto Neuroscience NYSE:ANRO

Eyepoint Pharmaceuticals NASDAQ:EYPT

Harrow NASDAQ:HROW

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools